Open Access Highly Accessed Study protocol

Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction

Charlie Strange1*, Felix JF Herth2, Kevin L Kovitz3, Geoffrey McLennan4, Armin Ernst5, Jonathan Goldin6, Marc Noppen7, Gerard J Criner8, Frank C Sciurba9 and the VENT Study Group10

Author Affiliations

1 Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, USA

2 Department of Pneumology and Critical Care Medicine, Thoraxklinik am Universtaetsklinikum, Heidelberg, Germany

3 Section of Pulmonary, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA

4 Colleges of Medicine and Engineering, University of Iowa, Iowa City, Iowa, USA

5 Division of Thoracic Surgery and Interventional Pulmonary, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

6 Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

7 Interventional Endoscopy Clinic, University Hospital AZ-VUB, Brussels, Belgium

8 Division of Pulmonary and Critical Care Medicine, Temple University School of Medicine, Philadelphia, PA, USA

9 Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, USA

10 the VENT Study Group is provided at the end of the article

For all author emails, please log on.

BMC Pulmonary Medicine 2007, 7:10  doi:10.1186/1471-2466-7-10

Published: 3 July 2007



Lung volume reduction surgery is effective at improving lung function, quality of life, and mortality in carefully selected individuals with advanced emphysema. Recently, less invasive bronchoscopic approaches have been designed to utilize these principles while avoiding the associated perioperative risks. The Endobronchial Valve for Emphysema PalliatioN Trial (VENT) posits that occlusion of a single pulmonary lobe through bronchoscopically placed Zephyr® endobronchial valves will effect significant improvements in lung function and exercise tolerance with an acceptable risk profile in advanced emphysema.


The trial design posted on Clinical, on August 10, 2005 proposed an enrollment of 270 subjects. Inclusion criteria included: diagnosis of emphysema with forced expiratory volume in one second (FEV1) < 45% of predicted, hyperinflation (total lung capacity measured by body plethysmography > 100%; residual volume > 150% predicted), and heterogeneous emphysema defined using a quantitative chest computed tomography algorithm. Following standardized pulmonary rehabilitation, patients were randomized 2:1 to receive unilateral lobar placement of endobronchial valves plus optimal medical management or optimal medical management alone. The co-primary endpoint was the mean percent change in FEV1 and six minute walk distance at 180 days. Secondary end-points included mean percent change in St. George's Respiratory Questionnaire score and the mean absolute changes in the maximal work load measured by cycle ergometry, dyspnea (mMRC) score, and total oxygen use per day. Per patient response rates in clinically significant improvement/maintenance of FEV1 and six minute walk distance and technical success rates of valve placement were recorded. Apriori response predictors based on quantitative CT and lung physiology were defined.


If endobronchial valves improve FEV1 and health status with an acceptable safety profile in advanced emphysema, they would offer a novel intervention for this progressive and debilitating disease.

Trial Registration NCT00129584